Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
BETHESDA, Md., April 10, 2017 -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces today that it has filed patent applications for IGC-501 in Canada, Israel, and Europe in support of its global cannabis-based combination therapy development initiatives.
IGC-501 is indicated for neuropathic pain. The pain market represents a significant component of the healthcare system and The Journal of Pain in September 2012 reported that the annual estimated national cost of pain ranges from $560 billion to $635 billion. In addition, abuse of prescription opioids is estimated to cost about $25 billion.
The international landscape embraces advancements in medical cannabis with countries like Germany, Israel and Canada being in the forefront. We aspire to bring our cannabis-based compounds to these markets and position ourselves for sustained growth. Canada’s recent introduction of legislation to legalize cannabis and Germany’s initiatives on medical cannabis are particularly encouraging on a global perspective. It should be noted that filing a patent does not guarantee that a patent will be issued in the future.
“We continue to strengthen our IP position in cannabis-based combination therapies and have progressed to include global patent filings. IGC is committed to addressing high potential international markets as a first mover in this emerging segment of cannabis-based combination therapy pharmaceuticals,” concludes Ram Mukunda, CEO.
About IGC
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.
For more information visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see risk factors discussed in India Globalization Capital, Inc.’s Form 10-K for fiscal year ended March 31, 2016, and in subsequent reports filed with the U.S. Securities and Exchange Commission.
Contact Info: Claudia Grimaldi 301-983-0998
